var data={"title":"Prevention of lethal opioid overdose in the community","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Prevention of lethal opioid overdose in the community</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/prevention-of-lethal-opioid-overdose-in-the-community/contributors\" class=\"contributor contributor_credentials\">Phillip Coffin, MD, MIA</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/prevention-of-lethal-opioid-overdose-in-the-community/contributors\" class=\"contributor contributor_credentials\">Andrew J Saxon, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/prevention-of-lethal-opioid-overdose-in-the-community/contributors\" class=\"contributor contributor_credentials\">Richard Hermann, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/prevention-of-lethal-opioid-overdose-in-the-community/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Apr 10, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H544614055\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Drug overdose, principally due to opioids, is rising in many developed countries; in the United States, for example, it has been the leading cause of injury-related death since 2009. The incidence of opioid overdose increased dramatically between 1990 and 2010. Opioid overdose is defined as opioid-induced respiratory depression such that assistance is needed to revive the person. &#160;</p><p>Interventions found to reduce mortality from opioid overdose include: treatment of opioid use disorder with an opioid agonist [<a href=\"https://www.uptodate.com/contents/prevention-of-lethal-opioid-overdose-in-the-community/abstract/1\" class=\"abstract_t\">1</a>], provision of <a href=\"topic.htm?path=naloxone-drug-information\" class=\"drug drug_general\">naloxone</a> to lay persons [<a href=\"https://www.uptodate.com/contents/prevention-of-lethal-opioid-overdose-in-the-community/abstract/2\" class=\"abstract_t\">2</a>], and establishment of a supervised injection facility [<a href=\"https://www.uptodate.com/contents/prevention-of-lethal-opioid-overdose-in-the-community/abstract/3\" class=\"abstract_t\">3</a>]. </p><p>This topic describes prevention of lethal opioid overdose in the community. The epidemiology, pharmacology, screening, assessment, diagnosis, and treatment of opioid use disorder are discussed separately. Management of intoxication and withdrawal from opioids are also discussed separately, as is abuse of prescription drugs.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=opioid-use-disorder-epidemiology-pharmacology-clinical-manifestations-course-screening-assessment-and-diagnosis\" class=\"medical medical_review\">&quot;Opioid use disorder: Epidemiology, pharmacology, clinical manifestations, course, screening, assessment, and diagnosis&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=psychosocial-interventions-for-opioid-use-disorder\" class=\"medical medical_review\">&quot;Psychosocial interventions for opioid use disorder&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=psychosocial-interventions-for-opioid-use-disorder\" class=\"medical medical_review\">&quot;Psychosocial interventions for opioid use disorder&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=medically-supervised-opioid-withdrawal-during-treatment-for-addiction\" class=\"medical medical_review\">&quot;Medically supervised opioid withdrawal during treatment for addiction&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=acute-opioid-intoxication-in-adults#H4\" class=\"medical medical_review\">&quot;Acute opioid intoxication in adults&quot;, section on 'Clinical features of overdose'</a> and <a href=\"topic.htm?path=overview-of-the-treatment-of-chronic-non-cancer-pain#H45602510\" class=\"medical medical_review\">&quot;Overview of the treatment of chronic non-cancer pain&quot;, section on 'Opioids'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=prescription-drug-misuse-epidemiology-prevention-identification-and-management\" class=\"medical medical_review\">&quot;Prescription drug misuse: Epidemiology, prevention, identification, and management&quot;</a>.)</p><p/><p class=\"headingAnchor\" id=\"H544614808\"><span class=\"h1\">EPIDEMIOLOGY OF OVERDOSE</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Opioid overdose was the main cause of an estimated 99,000 to 253,000 deaths worldwide related to illicit drug use in 2010 [<a href=\"https://www.uptodate.com/contents/prevention-of-lethal-opioid-overdose-in-the-community/abstract/4\" class=\"abstract_t\">4</a>]. In the United States, drug overdose deaths nearly tripled to 47,055 during 1999 to 2014, with 60.9 percent involving an opioid. </p><p>The rise in lethal opioid overdoses has been seen with prescription opioids, heroin, and synthetic opioids other than <a href=\"topic.htm?path=methadone-drug-information\" class=\"drug drug_general\">methadone</a>:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Mortality rates from drug overdoses involving <a href=\"topic.htm?path=methadone-drug-information\" class=\"drug drug_general\">methadone</a> declined by 9.1 percent in 2015 in the United States, while drug overdoses involving heroin and synthetic opioids other than methadone increased sharply [<a href=\"https://www.uptodate.com/contents/prevention-of-lethal-opioid-overdose-in-the-community/abstract/5\" class=\"abstract_t\">5</a>]. The rise in overdoses from synthetic opioids was likely driven by illicitly manufactured <a href=\"topic.htm?path=fentanyl-drug-information\" class=\"drug drug_general\">fentanyl</a>, a highly potent opioid often used to &ldquo;cut&rdquo; heroin.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In a study of 295 deaths from opioid overdose, 44 percent had been prescribed opioids [<a href=\"https://www.uptodate.com/contents/prevention-of-lethal-opioid-overdose-in-the-community/abstract/6\" class=\"abstract_t\">6</a>]. A higher prescribed dose of opioids was found to be associated with greater risk of overdose death in several studies [<a href=\"https://www.uptodate.com/contents/prevention-of-lethal-opioid-overdose-in-the-community/abstract/7-9\" class=\"abstract_t\">7-9</a>]. Patients with chronic pain who were prescribed a daily dose of 100 mg or more of <a href=\"topic.htm?path=morphine-drug-information\" class=\"drug drug_general\">morphine</a> (or other opioids in morphine equivalent doses) had a nine and sevenfold greater risk of overdose death, respectively, compared with patients prescribed 20 mg per day or less in two studies [<a href=\"https://www.uptodate.com/contents/prevention-of-lethal-opioid-overdose-in-the-community/abstract/8,9\" class=\"abstract_t\">8,9</a>]. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The age-adjusted rate for heroin-related drug-poisoning deaths nearly tripled from 1.0 per 100,000 in 2010 to 2.7 per 100,000 in 2013 [<a href=\"https://www.uptodate.com/contents/prevention-of-lethal-opioid-overdose-in-the-community/abstract/10\" class=\"abstract_t\">10</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Mortality from overdoses involving opioid analgesics more than tripled from 1999 to 2013 [<a href=\"https://www.uptodate.com/contents/prevention-of-lethal-opioid-overdose-in-the-community/abstract/10-13\" class=\"abstract_t\">10-13</a>]. From 2010 to 2013, opioid analgesic overdose deaths stabilized, while heroin overdose deaths increased 37 percent per year, resulting in an ongoing rise in opioid overdose mortality in the United States [<a href=\"https://www.uptodate.com/contents/prevention-of-lethal-opioid-overdose-in-the-community/abstract/10-13\" class=\"abstract_t\">10-13</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A study of nationally representative data on United States emergency department (ED) visits found that the population-based rate of ED visits for opioid overdose nearly quadrupled from 1993 to 2010 [<a href=\"https://www.uptodate.com/contents/prevention-of-lethal-opioid-overdose-in-the-community/abstract/14,15\" class=\"abstract_t\">14,15</a>]. Approximately 731,000 ED visits (95% CI 586,000-877,000 visits) for opioid overdose occurred over the 18-year period; overdose rates increased from 7 to 27 visits per 100,000 population from 1993-94 to 2009-10. </p><p/><p class=\"headingAnchor\" id=\"H544615086\"><span class=\"h2\">Risk factors</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Overdose can occur at any time with any opioid agonist. A prior overdose is the strongest predictor of a future overdose and of overdose death [<a href=\"https://www.uptodate.com/contents/prevention-of-lethal-opioid-overdose-in-the-community/abstract/16\" class=\"abstract_t\">16</a>]. Factors associated with increased risk of overdose include [<a href=\"https://www.uptodate.com/contents/prevention-of-lethal-opioid-overdose-in-the-community/abstract/17\" class=\"abstract_t\">17</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Co-occurring use of sedatives or alcohol, which are also respiratory depressants; epidemiologic data also suggest elevated risk with consumption of cocaine.</p><p/><p class=\"bulletIndent1\">As an example, in a retrospective claims-data analysis of 315,428 privately insured patients prescribed opioid medication, the proportion who concurrently received a benzodiazepine increased from 9 to 17 percent between 2001 and 2013 [<a href=\"https://www.uptodate.com/contents/prevention-of-lethal-opioid-overdose-in-the-community/abstract/18\" class=\"abstract_t\">18</a>]. Concurrent use of both opioid and benzodiazepine medications was associated with an increased risk of an emergency room visit or inpatient admission for opioid overdose compared with patients receiving an opioid but not a benzodiazepine (adjusted odds ratio = 2.14, 95% CI 2.05-2.24). </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Recent abstinence &ndash; A period of abstinence increases the risk of overdose from relapse by lowering the patient's tolerance to opioids. A dose that would have had minimal effects on the patient when physiologically dependent can cause overdose in the abstinent patient. Patients may be at risk due to abstinence after release from incarceration, during hospitalization or after discharge, or following medically supervised withdrawal or abstinence-based treatment of opioid use disorder [<a href=\"https://www.uptodate.com/contents/prevention-of-lethal-opioid-overdose-in-the-community/abstract/19\" class=\"abstract_t\">19</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Use of illicit opioids, particularly when injected [<a href=\"https://www.uptodate.com/contents/prevention-of-lethal-opioid-overdose-in-the-community/abstract/19\" class=\"abstract_t\">19</a>]. Variations in the (often unknown) purity and potency of heroin account for approximately 15 percent of the variation in overdose fatality [<a href=\"https://www.uptodate.com/contents/prevention-of-lethal-opioid-overdose-in-the-community/abstract/20\" class=\"abstract_t\">20</a>]. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Among prescription opioid users, higher prescribed doses [<a href=\"https://www.uptodate.com/contents/prevention-of-lethal-opioid-overdose-in-the-community/abstract/21\" class=\"abstract_t\">21</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Co-occurring pulmonary disease or sleep apnea [<a href=\"https://www.uptodate.com/contents/prevention-of-lethal-opioid-overdose-in-the-community/abstract/22\" class=\"abstract_t\">22</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A genetic predisposition to the respiratory depressive effects of opioids [<a href=\"https://www.uptodate.com/contents/prevention-of-lethal-opioid-overdose-in-the-community/abstract/23\" class=\"abstract_t\">23</a>].</p><p/><p class=\"headingAnchor\" id=\"H178654\"><span class=\"h1\">CLINICAL FEATURES OF OVERDOSE</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Clinical features of opioid intoxication and overdose are discussed in detail separately, as is the pharmacology of opioids. Education on the clinical features of overdose is discussed below. (See <a href=\"topic.htm?path=acute-opioid-intoxication-in-adults#H2\" class=\"medical medical_review\">&quot;Acute opioid intoxication in adults&quot;, section on 'Pharmacology and cellular toxicology'</a> and <a href=\"topic.htm?path=acute-opioid-intoxication-in-adults#H4\" class=\"medical medical_review\">&quot;Acute opioid intoxication in adults&quot;, section on 'Clinical features of overdose'</a> and <a href=\"#H178800\" class=\"local\">'Overdose education'</a> below.)</p><p class=\"headingAnchor\" id=\"H544615120\"><span class=\"h1\">COMMUNITY-BASED INTERVENTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Opioid overdose prevention involves education and provision of take-home <a href=\"topic.htm?path=naloxone-drug-information\" class=\"drug drug_general\">naloxone</a> to patients at risk of an overdose, their caregivers, and household members. Participants are taught to recognize risk factors for overdose and signs and symptoms of overdose, and how to administer naloxone. &#160;</p><p class=\"headingAnchor\" id=\"H3948867050\"><span class=\"h2\">Who should receive?</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Based on guidelines from the CDC [<a href=\"https://www.uptodate.com/contents/prevention-of-lethal-opioid-overdose-in-the-community/abstract/24\" class=\"abstract_t\">24</a>] and other sources, we suggest that education and take-home <a href=\"topic.htm?path=naloxone-drug-information\" class=\"drug drug_general\">naloxone</a> be provided to patients with any of the following risk factors: </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Any illicit opioid use, with particular attention to:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Receiving or discontinuing treatment for opioid use disorder, including medication or behavioral therapies </p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>At risk of decreased tolerance due to recent abstinence, including release from prison or medically supervised opioid withdrawal</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Suspected opioid use disorder (mild, moderate or severe) [<a href=\"https://www.uptodate.com/contents/prevention-of-lethal-opioid-overdose-in-the-community/abstract/24\" class=\"abstract_t\">24</a>]</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Receiving prescribed opioids and any of the following:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Receiving &ge;50 <a href=\"topic.htm?path=morphine-drug-information\" class=\"drug drug_general\">morphine</a> milligram equivalents daily of prescribed opioids [<a href=\"https://www.uptodate.com/contents/prevention-of-lethal-opioid-overdose-in-the-community/abstract/24\" class=\"abstract_t\">24</a>]</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Concomitant use of other sedating drugs or medications, such as benzodiazepines [<a href=\"https://www.uptodate.com/contents/prevention-of-lethal-opioid-overdose-in-the-community/abstract/24\" class=\"abstract_t\">24</a>]</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Any history of a substance use disorder</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Any history of overdose from opioids [<a href=\"https://www.uptodate.com/contents/prevention-of-lethal-opioid-overdose-in-the-community/abstract/24\" class=\"abstract_t\">24</a>]</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Risk of witnessing an opioid overdose, if such practice is legally protected (see <a href=\"http://lawatlas.org/datasets/laws-regulating-administration-of-naloxone&amp;token=lxSvd9pKX3ePuOWk+Do5I4ofhv4+gMZiWxXXe8NXm4lo9uVIDyUJWjs3epHkrmP7s+SF9RA7rR3QdELydf9em+8XJhhfJQr2OkxwUkp5nwc=&amp;TOPIC_ID=99945\" target=\"_blank\" class=\"external\">lawatlas</a> for legal protections in US states)</p><p/><p>Misuse of prescribed opioids is also described separately, as are risk factors for overdose among patients treated with opioids for chronic pain. (See <a href=\"topic.htm?path=prescription-drug-misuse-epidemiology-prevention-identification-and-management#H29429864\" class=\"medical medical_review\">&quot;Prescription drug misuse: Epidemiology, prevention, identification, and management&quot;, section on 'Opioid analgesics'</a> and <a href=\"topic.htm?path=use-of-opioids-in-the-management-of-chronic-non-cancer-pain\" class=\"medical medical_review\">&quot;Use of opioids in the management of chronic non-cancer pain&quot;</a>.) &#160;</p><p class=\"headingAnchor\" id=\"H178788\"><span class=\"h2\">Components</span></p><p class=\"headingAnchor\" id=\"H178800\"><span class=\"h3\">Overdose education</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Many patients do not recognize opioid-induced respiratory depression requiring emergency medical care as &ldquo;overdose,&rdquo; but instead consider this to be an adverse reaction to medications [<a href=\"https://www.uptodate.com/contents/prevention-of-lethal-opioid-overdose-in-the-community/abstract/25\" class=\"abstract_t\">25</a>]. Participants in the preventive intervention receive education to help them identify people who are more likely to overdose, to recognize clinical signs of opioid overdose, and to intervene to prevent mortality:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Risk factors for overdose:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Use of illicit opioids</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Injection of opioids</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Use of other sedating substances with opioids</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Use after periods of reduced use or abstinence from opioids</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Certain comorbidities, such as lung disease or obstructive sleep apnea</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Recognition of overdose: </p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Nonresponsive</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Decreased or stopped breathing or heart rate</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Blue or purple cast to fingernails or fingertips</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Response to overdose:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Try to arouse patient by administering a firm sternal rub. (See <a href=\"topic.htm?path=stupor-and-coma-in-adults#H6\" class=\"medical medical_review\">&quot;Stupor and coma in adults&quot;, section on 'Level of consciousness'</a>.) &#160;</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>If in respiratory distress or not breathing, administer <a href=\"topic.htm?path=naloxone-drug-information\" class=\"drug drug_general\">naloxone</a>. (See <a href=\"#H544615212\" class=\"local\">'Administration'</a> below.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Call emergency medical services (EMS):</p><p/><p class=\"bulletIndent3\"><span class=\"glyph\">&#45;</span>911 in the United States</p><p class=\"bulletIndent3\"><span class=\"glyph\">&#45;</span>112 common in European Union countries</p><p class=\"bulletIndent3\"><span class=\"glyph\">&#45;</span>000 in Australia </p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Perform rescue breathing, chest compressions, or cardiopulmonary resuscitation (CPR), depending on respondent's skills and guidance from emergency dispatch. (See <a href=\"topic.htm?path=basic-life-support-bls-in-adults#H8\" class=\"medical medical_review\">&quot;Basic life support (BLS) in adults&quot;, section on 'Ventilations'</a>.) </p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Stay with the patient for at least three hours or until help arrives.</p><p/><p class=\"bulletIndent2\">Emergency medical services differ in whether they routinely transport all opioid overdose survivors to a hospital emergency department (ED) following <a href=\"topic.htm?path=naloxone-drug-information\" class=\"drug drug_general\">naloxone</a> administration. Some allow paramedics to send home patients who respond fully following an uncomplicated overdose of a short-acting opioid.</p><p/><p class=\"bulletIndent2\">In the absence of a paramedic or treating clinician, a patient should always go to the ED after <a href=\"topic.htm?path=naloxone-drug-information\" class=\"drug drug_general\">naloxone</a>. Patients who overdosed on a long-acting opioid may initially respond to naloxone but relapse when the antagonist wears off. Naloxone may also precipitate withdrawal, which can lead to further opioid use and possible overdose. </p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Place person on <span class=\"nowrap\">his/her</span> side to prevent aspiration after vomiting.</p><p/><p>Participant education takes approximately 5 to 10 minutes. A toolkit (<a href=\"http://store.samhsa.gov/shin/content//SMA13-4742/Overdose_Toolkit_2014_Jan.pdf&amp;token=Ej5+HxypbtrLyKVwURbeChCT19LnBBJ0SjhCRXcNz76YVbXtMENSAhLaffRrzU/AUMPp2/83ErvcFEnwo0MAS/5lTQ3UJmfwSPPhLunB+bMYSKUJbLdjFbiICbR+KtuO&amp;TOPIC_ID=99945\" target=\"_blank\" class=\"external\">accessible here</a>) developed by the Substance Abuse and Mental Health Services Administration in the United States provides lay educational material on the preventive intervention [<a href=\"https://www.uptodate.com/contents/prevention-of-lethal-opioid-overdose-in-the-community/abstract/26\" class=\"abstract_t\">26</a>]. </p><p>Materials to assist healthcare providers in prescribing, dispensing, or educating about <a href=\"topic.htm?path=naloxone-drug-information\" class=\"drug drug_general\">naloxone</a> are available at <a href=\"http://www.prescribetoprevent.org/&amp;token=nQSguVzTjd5giRWjBYiQc0Dzl4DpAz9KmdcFIbbzLO6Np1nDPHk8cCB8cOlwX4yR&amp;TOPIC_ID=99945\" target=\"_blank\" class=\"external\">www.prescribetoprevent.org</a>.</p><p>Limited data suggest that education on overdose recognition and response may be effective. A controlled trial of a brief education (5 to 10 minutes) in 10 current or former opioid abusers found that, compared with no education, participants receiving education were more likely to recognize opioid overdose, identify scenarios where <a href=\"topic.htm?path=naloxone-drug-information\" class=\"drug drug_general\">naloxone</a> was indicated, and report higher perceived competency in recognition [<a href=\"https://www.uptodate.com/contents/prevention-of-lethal-opioid-overdose-in-the-community/abstract/27,28\" class=\"abstract_t\">27,28</a>].</p><p class=\"headingAnchor\" id=\"H178806\"><span class=\"h3\">Community-based naloxone</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=naloxone-drug-information\" class=\"drug drug_general\">Naloxone</a> is an opioid antagonist that rapidly reverses the effects of opioid overdose. Since 1996, some state and local agencies, treatment programs, and community groups in the United States have prescribed or dispensed naloxone for use outside the clinical setting to opioid users, families, and other potential caregivers as part of overdose education and prevention programs. While prescribing naloxone to a patient who uses opioids has been determined to be within the realm of usual practice [<a href=\"https://www.uptodate.com/contents/prevention-of-lethal-opioid-overdose-in-the-community/abstract/29\" class=\"abstract_t\">29</a>], most US states have also passed legislation authorizing prescribers to provide naloxone through standing orders <span class=\"nowrap\">and/or</span> to potential overdose witnesses, and protecting those who administer naloxone from penalties for practicing medicine without a license. See the Public Health Law Atlas for details on naloxone and Good Samaritan laws at <a href=\"http://lawatlas.org/query?dataset=laws-regulating-administration-of-naloxone&amp;token=8ghod8WixOaSQso5OUwcVF5zQrKlGlsVafCfqQRoih7eWHk6/tCqEq9qxDgrXnt/fl/T1aeRki/Ly//HjXVrNvjKk6XjSsmViUJtfQ1+7Us=&amp;TOPIC_ID=99945\" target=\"_blank\" class=\"external\">http://lawatlas.org/query?dataset=laws-regulating-administration-of-naloxone</a>.</p><p class=\"headingAnchor\" id=\"H544615212\"><span class=\"h4\">Administration</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The usual adult dose of lay-administered <a href=\"topic.htm?path=naloxone-drug-information\" class=\"drug drug_general\">naloxone</a> in the event of an opioid overdose is 0.4 mg (0.4 <span class=\"nowrap\">mg/1</span> mL solution) when injected intravenously, intramuscularly, or subcutaneously. Facilitating drug delivery are:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=naloxone-drug-information\" class=\"drug drug_general\">Naloxone</a><strong> auto-injector</strong> &mdash; The US Food and Drug Administration (US FDA) in 2014 approved a handheld naloxone auto-injector (Evzio) intended to be <span class=\"nowrap\">prescribed/dispensed</span> for use by family members, caregivers, and others in the community [<a href=\"https://www.uptodate.com/contents/prevention-of-lethal-opioid-overdose-in-the-community/abstract/30\" class=\"abstract_t\">30</a>]. When activated, the device provides verbal instructions to the user and delivers an intramuscular or subcutaneous dose of naloxone (0.4 <span class=\"nowrap\">mg/0</span>.4 mL solution).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=naloxone-drug-information\" class=\"drug drug_general\">Naloxone</a><strong> intranasal spray</strong> &mdash; Naloxone intranasal spray (Narcan nasal spray) was approved in 2015 by the US FDA in a dispenser that delivers a premeasured 4 mg dose [<a href=\"https://www.uptodate.com/contents/prevention-of-lethal-opioid-overdose-in-the-community/abstract/31\" class=\"abstract_t\">31</a>]. Intranasal naloxone has previously been delivered using a mucosal atomizer (2 mg dose of 1 <span class=\"nowrap\">mg/1</span> mL solution). </p><p/><p class=\"bulletIndent1\">Two doses of <a href=\"topic.htm?path=naloxone-drug-information\" class=\"drug drug_general\">naloxone</a> are generally prescribed because repeated doses may be necessary if respiratory depression continues or recurs prior to EMS arrival. In approximately 25 percent of cases, lay responders report administering a second dose.</p><p/><p class=\"headingAnchor\" id=\"H544615246\"><span class=\"h4\">Efficacy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Analyses of survey, population, and mortality data, though methodologically limited, have reported associations between distribution of <a href=\"topic.htm?path=naloxone-drug-information\" class=\"drug drug_general\">naloxone</a> and reductions in opioid overdose death in communities. These data suggest that many opioid overdoses have been reversed with lay use of injected or intranasal naloxone. Examples include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A 2013 interrupted time series analysis in Massachusetts compared mortality rates related to opioid overdose in communities that did and did not implement overdose education and <a href=\"topic.htm?path=naloxone-drug-information\" class=\"drug drug_general\">naloxone</a> distribution programs, finding that communities implementing the program had reduced adjusted mortality rates compared with nonimplementing communities. The results suggested a &quot;dose-dependent&quot; trend in which the more naloxone distributed in a given community, the greater the relative reduction in opioid overdose mortality (adjusted relative risk of 0.73 in communities with 1 to 100 naloxone enrollments per 100,000 population, and 0.57 in communities with &gt;100 enrollments) [<a href=\"https://www.uptodate.com/contents/prevention-of-lethal-opioid-overdose-in-the-community/abstract/2\" class=\"abstract_t\">2</a>]. Programs enrolled 2912 participants in the intervention during a three-year period; enrollees reported 327 overdose reversals.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A 2014 meta-analysis of evaluations of <a href=\"topic.htm?path=naloxone-drug-information\" class=\"drug drug_general\">naloxone</a> studies found that lay administration of naloxone was associated with significantly increased odds of recovery compared with no lay naloxone administration (odds ratio 8.58, 95% CI 3.90-13.25) [<a href=\"https://www.uptodate.com/contents/prevention-of-lethal-opioid-overdose-in-the-community/abstract/32\" class=\"abstract_t\">32</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A 2015 survey of United States programs that distribute <a href=\"topic.htm?path=naloxone-drug-information\" class=\"drug drug_general\">naloxone</a> for lay use reported that 644 sites had provided naloxone to 152,283 laypersons and received reports of 26,463 reversals from 1996 to 2014 [<a href=\"https://www.uptodate.com/contents/prevention-of-lethal-opioid-overdose-in-the-community/abstract/33\" class=\"abstract_t\">33</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A 2016 observational study of <a href=\"topic.htm?path=naloxone-drug-information\" class=\"drug drug_general\">naloxone</a> prescription to patients who were prescribed long-term opioids for chronic pain found that receipt of naloxone was associated with a 47 percent decline in opioid-related emergency department visits over the ensuing year [<a href=\"https://www.uptodate.com/contents/prevention-of-lethal-opioid-overdose-in-the-community/abstract/34\" class=\"abstract_t\">34</a>]. </p><p/><p>Data on use of the handheld injection device have not yet been published.</p><p class=\"headingAnchor\" id=\"H544615312\"><span class=\"h4\">Adverse effects</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><a href=\"topic.htm?path=naloxone-drug-information\" class=\"drug drug_general\">Naloxone</a> has been used safely by emergency department personnel and first responders for many years. Two types of adverse events are seen:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Side effects of abrupt reversal of opioid effects include nausea, vomiting, tachycardia, elevated blood pressure, and tremulousness; these are typically transient in patients without underlying cardiovascular or pulmonary disease. Serious adverse effects may include seizures and cardiac arrest, which have been observed rarely. Studies of lay reversal have reported relatively low rates of adverse events. As an example, a study of 399 reversals reported vomiting in 13 percent, anger or &quot;dope sickness&quot; in 9 percent, and seizure-like activity in &lt;1 percent [<a href=\"https://www.uptodate.com/contents/prevention-of-lethal-opioid-overdose-in-the-community/abstract/35\" class=\"abstract_t\">35</a>]. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Reversal of overdose effects by <a href=\"topic.htm?path=naloxone-drug-information\" class=\"drug drug_general\">naloxone</a> may be temporary. The drug's half-life is brief. Antagonism may wane before opioids are fully eliminated from the person's body, leading to recurrence of respiratory depression. This may not be a problem clinically with short-acting opioids like heroin; large studies of patients reversed with naloxone by paramedics and then released without transport to the hospital have found little to no evidence of recurrence of overdose leading to fatality [<a href=\"https://www.uptodate.com/contents/prevention-of-lethal-opioid-overdose-in-the-community/abstract/36,37\" class=\"abstract_t\">36,37</a>].</p><p/><p class=\"headingAnchor\" id=\"H544615336\"><span class=\"h4\">Follow-up</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Because <a href=\"topic.htm?path=naloxone-drug-information\" class=\"drug drug_general\">naloxone</a>'s overdose-reversing effects can wear off, those who may administer naloxone should be advised to seek medical help and stay with the overdosed person for three hours. Some patients may need repeated doses of naloxone, particularly if long-acting opioids such as <a href=\"topic.htm?path=methadone-drug-information\" class=\"drug drug_general\">methadone</a> are involved. </p><p class=\"headingAnchor\" id=\"H1793708267\"><span class=\"h1\">SOCIETY GUIDELINE LINKS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See <a href=\"topic.htm?path=society-guideline-links-opioid-use-disorder-and-withdrawal\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: Opioid use disorder and withdrawal&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H544615657\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Drug overdose, principally due to opioids, is rising in many developed countries; in the United States, for example, it has been the leading cause of injury-related death since 2009. The incidence of opioid overdose increased dramatically between 1990 and 2010. Opioid overdose is defined as opioid-induced respiratory depression such that assistance is needed to revive the person. (See <a href=\"#H544614055\" class=\"local\">'Introduction'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The risk of overdose should be discussed with all patients who use opioids. Providers should clarify that &quot;overdose&quot; does not necessarily imply use of an abnormally large amount of opioids, but instead that respiratory depression from opioids that can occur for many reasons. (See <a href=\"#H178800\" class=\"local\">'Overdose education'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>We suggest that education and take-home <a href=\"topic.htm?path=naloxone-drug-information\" class=\"drug drug_general\">naloxone</a> be provided to patients with any of the following risk factors (<a href=\"grade.htm?i=5\" class=\"grade\">Grade 2B</a>) (see <a href=\"#H3948867050\" class=\"local\">'Who should receive?'</a> above): </p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Any illicit opioid use, with particular attention to:</p><p/><p class=\"bulletIndent3\"><span class=\"glyph\">&#45;</span>Receiving or discontinuing treatment for opioid use disorder, including medication or behavioral therapies</p><p/><p class=\"bulletIndent3\"><span class=\"glyph\">&#45;</span>At risk of decreased tolerance due to recent abstinence, including release from prison or medically supervised opioid withdrawal</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Suspected opioid use disorder (mild, moderate or severe) [<a href=\"https://www.uptodate.com/contents/prevention-of-lethal-opioid-overdose-in-the-community/abstract/24\" class=\"abstract_t\">24</a>]</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Receiving prescribed opioids and any of the following: </p><p/><p class=\"bulletIndent3\"><span class=\"glyph\">&#45;</span>Receiving &ge;50 <a href=\"topic.htm?path=morphine-drug-information\" class=\"drug drug_general\">morphine</a> milligram equivalents daily of prescribed opioids [<a href=\"https://www.uptodate.com/contents/prevention-of-lethal-opioid-overdose-in-the-community/abstract/24\" class=\"abstract_t\">24</a>]</p><p/><p class=\"bulletIndent3\"><span class=\"glyph\">&#45;</span>Concomitant use of other sedating drugs or medications, such as benzodiazepines </p><p/><p class=\"bulletIndent3\"><span class=\"glyph\">&#45;</span>Any history of a substance use disorder</p><p/><p class=\"bulletIndent3\"><span class=\"glyph\">&#45;</span>Any history of overdose from opioids </p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Risk of witnessing an opioid overdose, if such practice is legally protected (see <a href=\"http://lawatlas.org/datasets/laws-regulating-administration-of-naloxone&amp;token=lxSvd9pKX3ePuOWk+Do5I4ofhv4+gMZiWxXXe8NXm4lo9uVIDyUJWjs3epHkrmP7s+SF9RA7rR3QdELydf9em+8XJhhfJQr2OkxwUkp5nwc=&amp;TOPIC_ID=99945\" target=\"_blank\" class=\"external\">lawatlas</a> for legal protections in US states)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Intervention to prevent opioid overdose is comprised of education and provision of take-home <a href=\"topic.htm?path=naloxone-drug-information\" class=\"drug drug_general\">naloxone</a> to patients at risk of an overdose, their caregivers, and household members. Participants are taught to recognize risk factors for overdose and signs and symptoms of overdose, and how to administer naloxone. (See <a href=\"#H178800\" class=\"local\">'Overdose education'</a> above and <a href=\"#H544615212\" class=\"local\">'Administration'</a> above.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Take-home <a href=\"topic.htm?path=naloxone-drug-information\" class=\"drug drug_general\">naloxone</a> is available in easy-to-administer forms, using a voice-guided autoinjector or an intranasal spray to deliver fixed doses. </p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>The usual adult dose of <a href=\"topic.htm?path=naloxone-drug-information\" class=\"drug drug_general\">naloxone</a> is 0.4 mg when injected intravenously, intramuscularly, or subcutaneously; or 2 mg of the 1 <span class=\"nowrap\">mg/1</span> mL concentration when administered intranasally. </p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Repeat doses may be necessary if respiratory depression continues or recurs prior to emergency medical services arrival.</p><p/><p class=\"headingAnchor\" id=\"H544615998\"><span class=\"h1\">ACKNOWLEDGMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The editorial staff at UpToDate would like to acknowledge Eric Strain, MD, who contributed to an earlier version of this topic review. </p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/prevention-of-lethal-opioid-overdose-in-the-community/abstract/1\" class=\"nounderline abstract_t\">Schwartz RP, Gryczynski J, O'Grady KE, et al. Opioid agonist treatments and heroin overdose deaths in Baltimore, Maryland, 1995-2009. Am J Public Health 2013; 103:917.</a></li><li><a href=\"https://www.uptodate.com/contents/prevention-of-lethal-opioid-overdose-in-the-community/abstract/2\" class=\"nounderline abstract_t\">Walley AY, Xuan Z, Hackman HH, et al. Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: interrupted time series analysis. BMJ 2013; 346:f174.</a></li><li><a href=\"https://www.uptodate.com/contents/prevention-of-lethal-opioid-overdose-in-the-community/abstract/3\" class=\"nounderline abstract_t\">Marshall BD, Milloy MJ, Wood E, et al. Reduction in overdose mortality after the opening of North America's first medically supervised safer injecting facility: a retrospective population-based study. Lancet 2011; 377:1429.</a></li><li class=\"breakAll\">UNODC. World Drug Report 2012, Contract No: E.12.XI.1, United Nations Publication, New York 2012.</li><li><a href=\"https://www.uptodate.com/contents/prevention-of-lethal-opioid-overdose-in-the-community/abstract/5\" class=\"nounderline abstract_t\">Rudd RA, Seth P, David F, Scholl L. Increases in Drug and Opioid-Involved Overdose Deaths - United States, 2010-2015. MMWR Morb Mortal Wkly Rep 2016; 65:1445.</a></li><li><a href=\"https://www.uptodate.com/contents/prevention-of-lethal-opioid-overdose-in-the-community/abstract/6\" class=\"nounderline abstract_t\">Hall AJ, Logan JE, Toblin RL, et al. Patterns of abuse among unintentional pharmaceutical overdose fatalities. JAMA 2008; 300:2613.</a></li><li><a href=\"https://www.uptodate.com/contents/prevention-of-lethal-opioid-overdose-in-the-community/abstract/7\" class=\"nounderline abstract_t\">Paulozzi LJ, Kilbourne EM, Shah NG, et al. A history of being prescribed controlled substances and risk of drug overdose death. Pain Med 2012; 13:87.</a></li><li><a href=\"https://www.uptodate.com/contents/prevention-of-lethal-opioid-overdose-in-the-community/abstract/8\" class=\"nounderline abstract_t\">Dunn KM, Saunders KW, Rutter CM, et al. Opioid prescriptions for chronic pain and overdose: a cohort study. Ann Intern Med 2010; 152:85.</a></li><li><a href=\"https://www.uptodate.com/contents/prevention-of-lethal-opioid-overdose-in-the-community/abstract/9\" class=\"nounderline abstract_t\">Bohnert AS, Valenstein M, Bair MJ, et al. Association between opioid prescribing patterns and opioid overdose-related deaths. JAMA 2011; 305:1315.</a></li><li><a href=\"https://www.uptodate.com/contents/prevention-of-lethal-opioid-overdose-in-the-community/abstract/10\" class=\"nounderline abstract_t\">Hedegaard H, Chen LH, Warner M. Drug-poisoning deaths involving heroin: United States, 2000-2013. NCHS Data Brief 2015; :1.</a></li><li><a href=\"https://www.uptodate.com/contents/prevention-of-lethal-opioid-overdose-in-the-community/abstract/11\" class=\"nounderline abstract_t\">Dart RC, Surratt HL, Cicero TJ, et al. Trends in opioid analgesic abuse and mortality in the United States. N Engl J Med 2015; 372:241.</a></li><li><a href=\"https://www.uptodate.com/contents/prevention-of-lethal-opioid-overdose-in-the-community/abstract/12\" class=\"nounderline abstract_t\">Unick GJ, Rosenblum D, Mars S, Ciccarone D. Intertwined epidemics: national demographic trends in hospitalizations for heroin- and opioid-related overdoses, 1993-2009. PLoS One 2013; 8:e54496.</a></li><li><a href=\"https://www.uptodate.com/contents/prevention-of-lethal-opioid-overdose-in-the-community/abstract/13\" class=\"nounderline abstract_t\">Rudd RA, Paulozzi LJ, Bauer MJ, et al. Increases in heroin overdose deaths - 28 States, 2010 to 2012. MMWR Morb Mortal Wkly Rep 2014; 63:849.</a></li><li><a href=\"https://www.uptodate.com/contents/prevention-of-lethal-opioid-overdose-in-the-community/abstract/14\" class=\"nounderline abstract_t\">Hasegawa K, Espinola JA, Brown DF, Camargo CA Jr. Trends in U.S. emergency department visits for opioid overdose, 1993-2010. Pain Med 2014; 15:1765.</a></li><li class=\"breakAll\">Substance Abuse and Mental Health Services Administration, Drug Abuse Warning Network, 2011: National Estimates of Drug-Related Emergency Department Visits. HHS Publication No. (SMA) 13-4760, DAWN Series D-39. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2013.</li><li><a href=\"https://www.uptodate.com/contents/prevention-of-lethal-opioid-overdose-in-the-community/abstract/16\" class=\"nounderline abstract_t\">Coffin PO, Tracy M, Bucciarelli A, et al. Identifying injection drug users at risk of nonfatal overdose. Acad Emerg Med 2007; 14:616.</a></li><li><a href=\"https://www.uptodate.com/contents/prevention-of-lethal-opioid-overdose-in-the-community/abstract/17\" class=\"nounderline abstract_t\">Darke S, Zador D. Fatal heroin 'overdose': a review. Addiction 1996; 91:1765.</a></li><li><a href=\"https://www.uptodate.com/contents/prevention-of-lethal-opioid-overdose-in-the-community/abstract/18\" class=\"nounderline abstract_t\">Sun EC, Dixit A, Humphreys K, et al. Association between concurrent use of prescription opioids and benzodiazepines and overdose: retrospective analysis. BMJ 2017; 356:j760.</a></li><li><a href=\"https://www.uptodate.com/contents/prevention-of-lethal-opioid-overdose-in-the-community/abstract/19\" class=\"nounderline abstract_t\">Darke S, Hall W. Heroin overdose: research and evidence-based intervention. J Urban Health 2003; 80:189.</a></li><li><a href=\"https://www.uptodate.com/contents/prevention-of-lethal-opioid-overdose-in-the-community/abstract/20\" class=\"nounderline abstract_t\">Darke S, Hall W, Weatherburn D, Lind B. Fluctuations in heroin purity and the incidence of fatal heroin overdose. Drug Alcohol Depend 1999; 54:155.</a></li><li><a href=\"https://www.uptodate.com/contents/prevention-of-lethal-opioid-overdose-in-the-community/abstract/21\" class=\"nounderline abstract_t\">Chou R, Turner JA, Devine EB, et al. The effectiveness and risks of long-term opioid therapy for chronic pain: a systematic review for a National Institutes of Health Pathways to Prevention Workshop. Ann Intern Med 2015; 162:276.</a></li><li><a href=\"https://www.uptodate.com/contents/prevention-of-lethal-opioid-overdose-in-the-community/abstract/22\" class=\"nounderline abstract_t\">Chaparro LE, Furlan AD, Deshpande A, et al. Opioids compared with placebo or other treatments for chronic low back pain: an update of the Cochrane Review. Spine (Phila Pa 1976) 2014; 39:556.</a></li><li><a href=\"https://www.uptodate.com/contents/prevention-of-lethal-opioid-overdose-in-the-community/abstract/23\" class=\"nounderline abstract_t\">Angst MS, Lazzeroni LC, Phillips NG, et al. Aversive and reinforcing opioid effects: a pharmacogenomic twin study. Anesthesiology 2012; 117:22.</a></li><li><a href=\"https://www.uptodate.com/contents/prevention-of-lethal-opioid-overdose-in-the-community/abstract/24\" class=\"nounderline abstract_t\">Dowell D, Haegerich TM, Chou R. CDC Guideline for Prescribing Opioids for Chronic Pain--United States, 2016. JAMA 2016; 315:1624.</a></li><li><a href=\"https://www.uptodate.com/contents/prevention-of-lethal-opioid-overdose-in-the-community/abstract/25\" class=\"nounderline abstract_t\">Behar E, Rowe C, Santos GM, et al. Primary Care Patient Experience with Naloxone Prescription. Ann Fam Med 2016; 14:431.</a></li><li class=\"breakAll\">Substance Abuse and Mental Health Services Administration. Opioid Overdose Prevention Toolkit. Substance Abuse and Mental Health Services Administration; Rockville, MD, 2013.</li><li><a href=\"https://www.uptodate.com/contents/prevention-of-lethal-opioid-overdose-in-the-community/abstract/27\" class=\"nounderline abstract_t\">Green TC, Heimer R, Grau LE. Distinguishing signs of opioid overdose and indication for naloxone: an evaluation of six overdose training and naloxone distribution programs in the United States. Addiction 2008; 103:979.</a></li><li><a href=\"https://www.uptodate.com/contents/prevention-of-lethal-opioid-overdose-in-the-community/abstract/28\" class=\"nounderline abstract_t\">Behar E, Santos GM, Wheeler E, et al. Brief overdose education is sufficient for naloxone distribution to opioid users. Drug Alcohol Depend 2015; 148:209.</a></li><li><a href=\"https://www.uptodate.com/contents/prevention-of-lethal-opioid-overdose-in-the-community/abstract/29\" class=\"nounderline abstract_t\">Davis C, Webb D, Burris S. Changing law from barrier to facilitator of opioid overdose prevention. J Law Med Ethics 2013; 41 Suppl 1:33.</a></li><li class=\"breakAll\">http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm391465.htm (Accessed on April 30, 2014).</li><li class=\"breakAll\">FDA moves quickly to approve easy-to-use nasal spray to treat opioid overdose http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm473505.htm (Accessed on January 11, 2016).</li><li><a href=\"https://www.uptodate.com/contents/prevention-of-lethal-opioid-overdose-in-the-community/abstract/32\" class=\"nounderline abstract_t\">Giglio RE, Guohua L, DiMaggio CJ. Effectiveness of bystander naloxone administration and overdose education programs: a meta-analysis. Inj Epidemiol 2015; 2:1.</a></li><li><a href=\"https://www.uptodate.com/contents/prevention-of-lethal-opioid-overdose-in-the-community/abstract/33\" class=\"nounderline abstract_t\">Wheeler E, Jones TS, Gilbert MK, et al. Opioid Overdose Prevention Programs Providing Naloxone to Laypersons - United States, 2014. MMWR Morb Mortal Wkly Rep 2015; 64:631.</a></li><li><a href=\"https://www.uptodate.com/contents/prevention-of-lethal-opioid-overdose-in-the-community/abstract/34\" class=\"nounderline abstract_t\">Coffin PO, Behar E, Rowe C, et al. Nonrandomized Intervention Study of Naloxone Coprescription for Primary Care Patients Receiving Long-Term Opioid Therapy for Pain. Ann Intern Med 2016; 165:245.</a></li><li><a href=\"https://www.uptodate.com/contents/prevention-of-lethal-opioid-overdose-in-the-community/abstract/35\" class=\"nounderline abstract_t\">Enteen L, Bauer J, McLean R, et al. Overdose prevention and naloxone prescription for opioid users in San Francisco. J Urban Health 2010; 87:931.</a></li><li><a href=\"https://www.uptodate.com/contents/prevention-of-lethal-opioid-overdose-in-the-community/abstract/36\" class=\"nounderline abstract_t\">Rudolph SS, Jehu G, Nielsen SL, et al. Prehospital treatment of opioid overdose in Copenhagen--is it safe to discharge on-scene? Resuscitation 2011; 82:1414.</a></li><li><a href=\"https://www.uptodate.com/contents/prevention-of-lethal-opioid-overdose-in-the-community/abstract/37\" class=\"nounderline abstract_t\">Vilke GM, Sloane C, Smith AM, Chan TC. Assessment for deaths in out-of-hospital heroin overdose patients treated with naloxone who refuse transport. Acad Emerg Med 2003; 10:893.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 99945 Version 12.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H544615657\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H544614055\" id=\"outline-link-H544614055\">INTRODUCTION</a></li><li><a href=\"#H544614808\" id=\"outline-link-H544614808\">EPIDEMIOLOGY OF OVERDOSE</a><ul><li><a href=\"#H544615086\" id=\"outline-link-H544615086\">Risk factors</a></li></ul></li><li><a href=\"#H178654\" id=\"outline-link-H178654\">CLINICAL FEATURES OF OVERDOSE</a></li><li><a href=\"#H544615120\" id=\"outline-link-H544615120\">COMMUNITY-BASED INTERVENTION</a><ul><li><a href=\"#H3948867050\" id=\"outline-link-H3948867050\">Who should receive?</a></li><li><a href=\"#H178788\" id=\"outline-link-H178788\">Components</a><ul><li><a href=\"#H178800\" id=\"outline-link-H178800\">- Overdose education</a></li><li><a href=\"#H178806\" id=\"outline-link-H178806\">- Community-based naloxone</a><ul><li><a href=\"#H544615212\" id=\"outline-link-H544615212\">Administration</a></li><li><a href=\"#H544615246\" id=\"outline-link-H544615246\">Efficacy</a></li><li><a href=\"#H544615312\" id=\"outline-link-H544615312\">Adverse effects</a></li><li><a href=\"#H544615336\" id=\"outline-link-H544615336\">Follow-up</a></li></ul></li></ul></li></ul></li><li><a href=\"#H1793708267\" id=\"outline-link-H1793708267\">SOCIETY GUIDELINE LINKS</a></li><li><a href=\"#H544615657\" id=\"outline-link-H544615657\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#H544615998\" id=\"outline-link-H544615998\">ACKNOWLEDGMENT</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=acute-opioid-intoxication-in-adults\" class=\"medical medical_review\">Acute opioid intoxication in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=basic-life-support-bls-in-adults\" class=\"medical medical_review\">Basic life support (BLS) in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=medically-supervised-opioid-withdrawal-during-treatment-for-addiction\" class=\"medical medical_review\">Medically supervised opioid withdrawal during treatment for addiction</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=opioid-use-disorder-epidemiology-pharmacology-clinical-manifestations-course-screening-assessment-and-diagnosis\" class=\"medical medical_review\">Opioid use disorder: Epidemiology, pharmacology, clinical manifestations, course, screening, assessment, and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-the-treatment-of-chronic-non-cancer-pain\" class=\"medical medical_review\">Overview of the treatment of chronic non-cancer pain</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=prescription-drug-misuse-epidemiology-prevention-identification-and-management\" class=\"medical medical_review\">Prescription drug misuse: Epidemiology, prevention, identification, and management</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=psychosocial-interventions-for-opioid-use-disorder\" class=\"medical medical_review\">Psychosocial interventions for opioid use disorder</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-opioid-use-disorder-and-withdrawal\" class=\"medical medical_society_guidelines\">Society guideline links: Opioid use disorder and withdrawal</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=stupor-and-coma-in-adults\" class=\"medical medical_review\">Stupor and coma in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=use-of-opioids-in-the-management-of-chronic-non-cancer-pain\" class=\"medical medical_review\">Use of opioids in the management of chronic non-cancer pain</a></li></ul></div></div>","javascript":null}